DMT

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

Jul 11, 2022

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

Jun 22, 2022

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Jun 7, 2022

Small Pharma Shares Business Update Ahead of Annual Financial Results

May 25, 2022

MindMed: The Future Of Biotech Pipelines

Apr 19, 2022

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT…

Apr 19, 2022

Psychedelics Activists In Massachusetts Push For Vote On Decriminalization

Apr 18, 2022

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Apr 13, 2022

Michigan Is On The Edge Of Decriminalizing Psychedelics

Apr 5, 2022

The First-Ever Clinical Trial For DMT Use In Major Depressive Disorder Show Promise

Feb 22, 2022